

ATRIPLA®
Country-by-Country Registration Status*
May 2010

Approved	Filed	Available
1. Botswana	1. Angola ^	1. Angola
2. Bolivia	2. Benin	2. Antigua and Barbuda
	3. Cape Verde	3. Bahamas
		4. Barbados
3. Burkina Faso	4. Djibouti	5. Belize
4. Burundi	5. Dominican Republic	6. Cambodia
5. Cameroon	6. Ghana	7. Dominica
6. Central African Republic	7. Guinea – Bissau ^	8. Grenada
7. Chad	8. Madagascar	9. Guyana
8. Congo-Brazzaville	9. Maldives	10. Haiti
9. Congo-Kinshasa	10. Mali	11. Kiribati
10. Cote d'Ivoire	11. Mauritius	12. Lao Republic
	12. Namibia	
11. Equatorial Guinea	13. Niger	13. Mongolia
12. Ethiopia	14. Rwanda	14. Nepal
13. Gabon	15. South Africa	15. Papua New Guinea
14. Gambia	16. Syria	16. Saint Kitts and Nevis
15. Guinea	17. Togo	17. Saint Lucia
	18. Trinidad & Tobago	
		18. Saint Vincent and Grenadines
16. Guatemala		19. Samoa
17. Honduras		20. Solomon Islands
18. Jamaica		21. Suriname
19. Kenya		
20. Malawi		22. Timor-Leste
21. Mauritania		23. Tuvalu
22. Mozambique		
23. Namibia		24. Vanuatu
24. Nicaragua		25. Yemen
25. Nigeria		
26. Panama		
27. Senegal		
28. Tanzania		
29. Uganda		
30. Ukraine		
31. Zambia		

ATRIPLA®
Country-by-Country Registration Status*
May 2010

Disclaimer: There can be no guarantee that marketing approval for ATRIPLA® will be granted in any of the countries where registration is pending, and any marketing approval, if granted, may have significant limitations on its use.

Terms and Definitions

Approved: Countries where the dossier has been submitted and approved

Filed: Countries where the dossier has been submitted and review is pending

Available: Countries where Merck makes ATRIPLA® available through locally acceptable alternative mechanisms

*: ATRIPLA® is a trademark of Bristol-Myers Squibb and Gilead Sciences, LLC. ATRIPLA® is marketed by Bristol-Myers Squibb and Gilead in the United States, Canada, the European Union, Norway and Iceland

^: Countries where Merck makes ATRIPLA® available prior to marketing approval through locally acceptable mechanisms